Welcome to our dedicated page for FEMASYS SEC filings (Ticker: FEMY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Femasys Inc. SEC filings document the company’s women’s health medical-device business, Nasdaq-listed common stock, operating results, and product-related corporate updates. Recent 8-K filings furnish quarterly and annual financial results and disclose material events tied to executive appointments, employment agreements, financing instruments, and listing compliance matters.
Proxy materials cover annual and special stockholder meetings, board elections and governance matters, reverse stock split authorization, and share-issuance approvals linked to capital-structure provisions. Other filings describe senior secured convertible notes, warrant amendments, Nasdaq minimum bid price compliance, and the company’s emerging growth company reporting status.
FEMASYS INC reported that executive Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, received a grant of stock options covering 6,250 shares of common stock. The options have an exercise price of $4.08 per share and expire on July 6, 2036. The underlying shares vest in equal installments over four years beginning on July 6, 2027, contingent on continued employment. Following this grant, Mifek holds options for 6,250 shares from this award.
FEMASYS INC reported that officer Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs, filed an initial ownership statement as a reporting person. He reports direct ownership of 1,411 shares of Common Stock. The filing also references an Exhibit 24 Power of Attorney authorizing representation in SEC matters.
Femasys Inc Chief Technology Officer Jeremy Alexander Sipos reported multiple transactions involving the company’s equity. He purchased 3,125 shares of common stock at $3.20 per share, for an aggregate $10,000, under a Securities Purchase Agreement dated August 7, 2026. On the same date, he was granted a warrant for 3,125 shares of common stock at an exercise price of $2.95 per share, exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. He also received a milestone warrant for 3,125 shares at $2.95 per share, exercisable only after a future Milestone Date tied to the company achieving $1,500,000 in U.S. revenue in any fiscal quarter and certain stock price conditions; the milestone warrant’s expiration is contingent and not yet determinable.
Femasys Inc. Chief Operating Officer John Charles Canning reported acquiring both common stock and warrants. He purchased 4,375 shares of common stock at $3.20 per share under a Securities Purchase Agreement, resulting in direct ownership of 4,375 common shares. He also received two grants of 4,375 common stock purchase warrants each, with an exercise price of $2.95 per share. One warrant series is exercisable from August 10, 2026 until August 10, 2029, while the milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. revenue for any fiscal quarter and meeting specified volume-weighted average price conditions, and is subject to exercise limitations under Nasdaq Capital Market rules.
Femasys Inc. Chief Financial Officer Dov Elefant reported new equity transactions. On August 7, 2026, he purchased 15,625 shares of common stock at $3.20 per share for an aggregate $50,000 under a Securities Purchase Agreement. He also received two direct grants of common stock purchase warrants, each for 15,625 shares at an exercise price of $2.95 per share. One warrant is exercisable from August 10, 2026 until August 10, 2029, subject to Nasdaq Capital Market limitations. The milestone warrant becomes exercisable only after a future Milestone Date tied to achieving $1,500,000 in U.S. quarterly revenue and specified volume-weighted average price conditions.
Femasys Inc. CEO Kathy Lee-Sepsick reported acquiring company securities on August 7, 2026. She purchased 15,625 shares of Common Stock at $3.20 per share, for an aggregate $50,000, under a Securities Purchase Agreement with Femasys and other purchasers. She also received a warrant for 15,625 shares exercisable at $2.95 per share from August 10, 2026 until August 10, 2029, and a separate Milestone warrant for 15,625 shares at the same exercise price, which becomes exercisable only after specified revenue and stock-price conditions are met and is subject to Nasdaq-related exercise limitations.
Femasys Inc. entered into a private placement with accredited investors to sell 5,013,559 shares of common stock, pre-funded warrants for 4,361,440 shares, and warrants for 18,749,998 shares at a purchase price of $3.20 per share (or $3.1999 per pre-funded warrant), for expected gross proceeds of approximately $30.0 million before expenses.
Pre-funded warrants are exercisable at $0.0001 per share with no expiration other than full exercise. Common and milestone warrants have a $2.95 exercise price and three-year terms, with milestone warrants exercisable only if the company achieves both $1,500,000 in U.S. revenue in any fiscal quarter and a volume-weighted average price at least 130% of the exercise price for 20 of 30 trading days. Exercise is capped at 4.99% or 9.99% beneficial ownership.
Nantahala Capital Management, as lead investor, obtained rights to designate up to two board members and one non-voting observer, subject to ownership thresholds, lasting up to ten years. Five company executives invested about $134,000 on the same terms. The securities are unregistered and rely on Section 4(a)(2) and Rule 506 of Regulation D, with agreed resale registration to be filed after closing. A prior lender terminated its separate board and observer nomination rights.
Femasys Inc. held its Annual Meeting of Stockholders, where holders of 1,487,447 shares of common stock, representing approximately 49.26% of shares eligible to vote, were present in person virtually or by proxy. All vote totals were adjusted for the 1-for-20 reverse stock split effective June 5, 2026.
Stockholders elected Charles Larsen and Kenneth Eichenbaum as Class II directors for three-year terms ending at the 2029 annual meeting, each receiving substantially more votes for than against. Stockholders also ratified the appointment of KPMG LLP as the independent registered accounting firm for the fiscal year ending December 31, 2026 by a wide margin.
Femasys Inc. has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share for continued listing on The Nasdaq Capital Market. The company achieved this after a 1-for-20 reverse stock split of its common stock became effective on June 5, 2026, and its closing bid price stayed at or above $1.00 for 10 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed. Femasys continues to focus on commercializing its fertility and non-surgical permanent birth control products and advancing clinical development of FemBloc.
Femasys Inc. implemented a 1-for-20 reverse stock split of its common stock, effective at 8:40 a.m. Eastern Time on June 5, 2026. Every 20 issued and outstanding shares were automatically combined into one share, with no change to the $0.001 par value.
The split applies to all outstanding shares and proportionately adjusts stock options, RSUs and warrants by reducing underlying share counts and increasing exercise prices. Shares reserved under the equity compensation plan were also reduced proportionately. Fractional shares will not be issued and will instead be rounded up to the next whole share at the DTC participant level.
The reverse split affects all stockholders proportionately, so percentage ownership is unchanged apart from minor effects from fractional share rounding. Femasys common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis on June 8, 2026, under a new CUSIP number 31447E 204.